Please enable JavaScript to continue using this application.

Compare $CCCC vs $GALT | Chartloom

Compare

$CCCC vs $GALT

C4 Therapeutics, Inc · Galectin Therapeutics Inc

CCCC

C4 Therapeutics, Inc

GALT

Galectin Therapeutics Inc

Compare $CCCC vs $GALT

Comparing C4 Therapeutics, Inc and Galectin Therapeutics Inc

CCCCC4 Therapeutics, Inc

GALTGalectin Therapeutics Inc

CCCCC4 Therapeutics, Inc

Market cap

$349M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

15.01x

Rev growth (TTM)

2.3%

YTD performance

63.7%

52W performance

41.7%

FCF yield

-24.4%

GALTGalectin Therapeutics Inc

Market cap

$259M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-2.7%

52W performance

-16.9%

FCF yield

-6.1%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CCCC

GALT

Detailed metrics comparison

CCCC

C4 Therapeutics, Inc

GALT

Galectin Therapeutics Inc

Market Cap

CCCC$349M

GALT$259M

Enterprise Value

CCCC$271M

GALT$384M

Price

CCCC$3.16

GALT$3.94

P/E Ratio

CCCCN/A

GALTN/A

P/S Ratio

CCCC9.97x

GALT0.00x

EV/Sales

CCCC7.73x

GALT0.00x

EV/EBITDA

CCCC0.00x

GALT0.00x

P/B Ratio

CCCC1.47x

GALT150.12x

P/FCF Ratio

CCCCN/A

GALTN/A

EV/FCF

CCCC-3.17x

GALT-24.16x

PEG Ratio

CCCCN/A

GALTN/A

Forward P/E (NTM)

CCCCN/A

GALTN/A

Forward P/S (NTM)

CCCC15.01x

GALTN/A

Revenue (TTM)

CCCC$35M

GALT$0

Revenue Growth (YoY)

CCCC2.3%

GALTN/A

Forward Rev Growth

CCCC-15.9%

GALT0.0%

Gross Margin (TTM)

CCCC0.0%

GALT0.0%

Operating Margin (TTM)

CCCC0.0%

GALT0.0%

EBITDA Margin (TTM)

CCCC-283.8%

GALT0.0%

Net Margin (TTM)

CCCC-289.4%

GALT0.0%

FCF Margin (TTM)

CCCC-243.7%

GALTN/A

Net Income (TTM)

CCCC$-101M

GALT$-28M

FCF (TTM)

CCCC$-85M

GALT$-16M

EPS (TTM)

CCCC-$0.78

GALT-$0.43

ROE (TTM)

CCCC-4545.0%

GALT-25862.0%

ROA (TTM)

CCCC-3090.0%

GALT-17683.0%

ROIC (TTM)

CCCC-4545.0%

GALT-11607.0%

Cash

CCCC$79M

GALT$13M

Debt

CCCC$0

GALT$138M

Net Cash/Debt

CCCC$79M

GALT$-124M

Current Ratio (TTM)

CCCC5.45x

GALT0.10x

Quick Ratio (TTM)

CCCC5.29x

GALT0.09x

Debt/Equity (TTM)

CCCC0.00x

GALT11.09x

Debt/Assets (TTM)

CCCC0.0%

GALT0.0%

Interest Coverage (TTM)

CCCCN/A

GALTN/A

Net Debt/EBITDA (TTM)

CCCC0.00x

GALT0.00x

Beta

CCCC3.16

GALT0.50

52W Performance

CCCC41.7%

GALT-16.9%

YTD Performance

CCCC63.7%

GALT-2.7%

% from 52W High

CCCC-38.9%

GALT-44.7%

% from 52W Low

CCCC87.0%

GALT94.6%

Asset Turnover (TTM)

CCCC0.11x

GALT0.00x

FCF Yield (TTM)

CCCC-24.4%

GALT-6.1%

Earnings Yield (TTM)

CCCC-29.0%

GALT-10.8%

Dividend Yield (TTM)

CCCCN/A

GALTN/A

Rule of 40

CCCC-241.4

GALT0.0

EV/GP/RG

CCCCN/A

GALTN/A

Ticker research

View CCCC research View GALT research

Metric	CCCC C4 Therapeutics, Inc	GALT Galectin Therapeutics Inc
Market & Valuation
Market Cap	$349M	$259M
Enterprise Value	$271M	$384M
Price	$3.16	$3.94
P/E Ratio	N/A	N/A
P/S Ratio	9.97x	0.00x
EV/Sales	7.73x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.47x	150.12x
P/FCF Ratio	N/A	N/A
EV/FCF	-3.17x	-24.16x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	15.01x	N/A
Revenue & Growth
Revenue (TTM)	$35M	$0
Revenue Growth (YoY)	2.3%	N/A
Forward Rev Growth	-15.9%	0.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-283.8%	0.0%
Net Margin (TTM)	-289.4%	0.0%
FCF Margin (TTM)	-243.7%	N/A
Net Income (TTM)	$-101M	$-28M
FCF (TTM)	$-85M	$-16M
EPS (TTM)	-$0.78	-$0.43
ROE (TTM)	-4545.0%	-25862.0%
ROA (TTM)	-3090.0%	-17683.0%
ROIC (TTM)	-4545.0%	-11607.0%
Financial Health
Cash	$79M	$13M
Debt	$0	$138M
Net Cash/Debt	$79M	$-124M
Current Ratio (TTM)	5.45x	0.10x
Quick Ratio (TTM)	5.29x	0.09x
Debt/Equity (TTM)	0.00x	11.09x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	3.16	0.50
52W Performance	41.7%	-16.9%
YTD Performance	63.7%	-2.7%
% from 52W High	-38.9%	-44.7%
% from 52W Low	87.0%	94.6%
Efficiency & Yields
Asset Turnover (TTM)	0.11x	0.00x
FCF Yield (TTM)	-24.4%	-6.1%
Earnings Yield (TTM)	-29.0%	-10.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-241.4	0.0
EV/GP/RG	N/A	N/A
Ticker research	View CCCC research	View GALT research

Valuation

P/S Ratio

GALT

0.00x

CCCC

9.97x

EV/FCF

GALT

-24.16x

CCCC

-3.17x

Growth & revenue

Revenue Growth TTM

CCCC

2.3%

Forward Revenue Growth

GALT

0.0%

CCCC

-15.9%

Profitability & performance

Gross Margin

CCCC

0.0%

GALT

0.0%

ROE

CCCC

-4545.0%

GALT

-25862.0%

FCF Yield %

GALT

-6.1%

CCCC

-24.4%

52-Week Performance

CCCC

41.7%

GALT

-16.9%

Detailed metrics comparison

CCCC

C4 Therapeutics, Inc

GALT

Galectin Therapeutics Inc

Market Cap

CCCC$349M

GALT$259M

Enterprise Value

CCCC$271M

GALT$384M

Price

CCCC$3.16

GALT$3.94

P/E Ratio

CCCCN/A

GALTN/A

P/S Ratio

CCCC9.97x

GALT0.00x

EV/Sales

CCCC7.73x

GALT0.00x

EV/EBITDA

CCCC0.00x

GALT0.00x

P/B Ratio

CCCC1.47x

GALT150.12x

P/FCF Ratio

CCCCN/A

GALTN/A

EV/FCF

CCCC-3.17x

GALT-24.16x

PEG Ratio

CCCCN/A

GALTN/A

Forward P/E (NTM)

CCCCN/A

GALTN/A

Forward P/S (NTM)

CCCC15.01x

GALTN/A

Revenue (TTM)

CCCC$35M

GALT$0

Revenue Growth (YoY)

CCCC2.3%

GALTN/A

Forward Rev Growth

CCCC-15.9%

GALT0.0%

Gross Margin (TTM)

CCCC0.0%

GALT0.0%

Operating Margin (TTM)

CCCC0.0%

GALT0.0%

EBITDA Margin (TTM)

CCCC-283.8%

GALT0.0%

Net Margin (TTM)

CCCC-289.4%

GALT0.0%

FCF Margin (TTM)

CCCC-243.7%

GALTN/A

Net Income (TTM)

CCCC$-101M

GALT$-28M

FCF (TTM)

CCCC$-85M

GALT$-16M

EPS (TTM)

CCCC-$0.78

GALT-$0.43

ROE (TTM)

CCCC-4545.0%

GALT-25862.0%

ROA (TTM)

CCCC-3090.0%

GALT-17683.0%

ROIC (TTM)

CCCC-4545.0%

GALT-11607.0%

Cash

CCCC$79M

GALT$13M

Debt

CCCC$0

GALT$138M

Net Cash/Debt

CCCC$79M

GALT$-124M

Current Ratio (TTM)

CCCC5.45x

GALT0.10x

Quick Ratio (TTM)

CCCC5.29x

GALT0.09x

Debt/Equity (TTM)

CCCC0.00x

GALT11.09x

Debt/Assets (TTM)

CCCC0.0%

GALT0.0%

Interest Coverage (TTM)

CCCCN/A

GALTN/A

Net Debt/EBITDA (TTM)

CCCC0.00x

GALT0.00x

Beta

CCCC3.16

GALT0.50

52W Performance

CCCC41.7%

GALT-16.9%

YTD Performance

CCCC63.7%

GALT-2.7%

% from 52W High

CCCC-38.9%

GALT-44.7%

% from 52W Low

CCCC87.0%

GALT94.6%

Asset Turnover (TTM)

CCCC0.11x

GALT0.00x

FCF Yield (TTM)

CCCC-24.4%

GALT-6.1%

Earnings Yield (TTM)

CCCC-29.0%

GALT-10.8%

Dividend Yield (TTM)

CCCCN/A

GALTN/A

Rule of 40

CCCC-241.4

GALT0.0

EV/GP/RG

CCCCN/A

GALTN/A

Ticker research

View CCCC research View GALT research

Metric	CCCC C4 Therapeutics, Inc	GALT Galectin Therapeutics Inc
Market & Valuation
Market Cap	$349M	$259M
Enterprise Value	$271M	$384M
Price	$3.16	$3.94
P/E Ratio	N/A	N/A
P/S Ratio	9.97x	0.00x
EV/Sales	7.73x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.47x	150.12x
P/FCF Ratio	N/A	N/A
EV/FCF	-3.17x	-24.16x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	15.01x	N/A
Revenue & Growth
Revenue (TTM)	$35M	$0
Revenue Growth (YoY)	2.3%	N/A
Forward Rev Growth	-15.9%	0.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-283.8%	0.0%
Net Margin (TTM)	-289.4%	0.0%
FCF Margin (TTM)	-243.7%	N/A
Net Income (TTM)	$-101M	$-28M
FCF (TTM)	$-85M	$-16M
EPS (TTM)	-$0.78	-$0.43
ROE (TTM)	-4545.0%	-25862.0%
ROA (TTM)	-3090.0%	-17683.0%
ROIC (TTM)	-4545.0%	-11607.0%
Financial Health
Cash	$79M	$13M
Debt	$0	$138M
Net Cash/Debt	$79M	$-124M
Current Ratio (TTM)	5.45x	0.10x
Quick Ratio (TTM)	5.29x	0.09x
Debt/Equity (TTM)	0.00x	11.09x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	3.16	0.50
52W Performance	41.7%	-16.9%
YTD Performance	63.7%	-2.7%
% from 52W High	-38.9%	-44.7%
% from 52W Low	87.0%	94.6%
Efficiency & Yields
Asset Turnover (TTM)	0.11x	0.00x
FCF Yield (TTM)	-24.4%	-6.1%
Earnings Yield (TTM)	-29.0%	-10.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-241.4	0.0
EV/GP/RG	N/A	N/A
Ticker research	View CCCC research	View GALT research